BR Biomedical Reports 2049-9434 2049-9442 D.A. Spandidos 10.3892/br.2020.1303 BR-0-0-1303 Articles Tissue gene mutation profiles in patients with colorectal cancer and their clinical implications YeJun 1 LinMei 1 ZhangChuanmeng 1 ZhuXiaowei 1 LiSumeng 1 LiuHui 2 YinJianfeng 3 YuHong 1 ZhuKuichun 4 5 Taizhou People's Hospital, The Center for Translational Medicine, Taizhou, Jiangsu 225300, P.R. China Xuzhou Medical University, Department of Pathology, Xuzhou, Jiangsu 221000, P.R. China Jianwei Medical Laboratory, Taizhou, Jiangsu 225300, P.R. China R&D Department, Labway Clinical Laboratories, Shanghai 210000, P.R. China R&D Department, Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd., Wuxi, Jiangsu 214000, P.R. China Correspondence to: Dr Kuichun Zhu, R&D Department, Wuxi Shenrui Bio-Pharmaceuticals Co., Ltd., 1699 Huishan Boulevard, Wuxi, Jiangsu 214000, P.R. China kzhu68@hotmail.com

Dr Hong Yu, Taizhou People's Hospital, The Center for Translational Medicine, 399 South Hailing Road, Taizhou, Jiangsu 225300, P.R. China yuhongjianglin@163.com

 07 2020 12 05 2020 13 1 43 48 07 11 2019 03 04 2020 Copyright © 2020, Spandidos Publications 2020

Colorectal cancer (CRC) is one of the most common types of cancer in the world, and targeted therapy is frequently used in the clinical management of the disease. A complete and accurate picture of tissue gene mutations is therefore critical. Tissue specimens from 117 patients with CRC were used for high throughput DNA next-generation sequencing (NGS) analysis. Hotspots from 50 genes frequently associated with the development and progression of solid tumors were targeted for sequencing. Characterization of tissue gene mutations was performed; the tissue mutation positive rates of KRAS, KIT, PIK3CA, MET and EGFR were 52.1, 19.7, 29.9, 15.4 and 14.5%, respectively. The mutation positive rates of TP53, APC, CDKN2A, STK11 and FBXW7 were 65.8, 39.3, 32.5, 19.7 and 19.7%, respectively. The most frequent KRAS mutations were G12A/C/D/S/V, accounting for 61.2% of all KRAS mutations. The most frequent TP53 mutations were R273C/G/H/L, accounting for 8.5% of all TP53 mutations. The most frequent APC mutation was E1554fs, accounting for 19.7% of all APC mutations. IDH1 R132C/H, KIT M541L, MET N375S, and SMAD4 R361C/H were also frequently identified. TP53 mutations were more common in patients ≥60 years old (P<0.05), and IDH1 mutations were more common in male patients (P<0.05). NGS 50 gene panel sequencing provides a comprehensive tissue gene mutation profile which may significantly improve clinical management.

 colorectal cancer gene mutation targeted therapy next-generation sequencing Introduction

Colorectal cancer (CRC) is the fourth most common type of cancer in terms of incidence and the third leading cause of cancer-associated death in the world (1). In the last decade the incidence and the mortality rates of CRC have decreased in the US and some European countries; however, both the incidence and the mortality rates of CRC in China have increased (2,3). The yearly global burden of CRC is estimated to be 2.2 million new cases and 1.1 million deaths by 2030(2).

The majority of cases of CRC cases are sporadic, and hereditary CRC accounts for ~5%. CRC is a heterogeneous disease, and several oncogenes and tumor suppressor genes, such as TP53, KRAS, APC and CDKN2A, are involved in its development (4-6). Gene mutations are the basis for selection of targeted agents for the treatment of various types of malignancy. There are targeted drugs, such as anti-EGFR agents and anti-VEGF/VEGFR agents, that are used in combination with surgery and chemotherapy (4,7,8). Therefore, accurate identification of gene mutations in patients with CRC is critical for selecting therapeutic agents, and predicting efficacy and prognosis.

High throughput DNA sequencing (NGS) technology has been widely used in research as well as clinically. NGS provides sequencing data in quantities orders of magnitude higher than Sanger sequencing, and with much greater sensitivity (9). NGS has been used for detection of gene mutations in CRC using DNA from tissue sections, blood and stool (10-15). Pooling of large quantities of data of gene mutations from tumor tissues and determining their associations with the clinicopathological characteristics may provide important information regarding the pathogenesis of CRC, and thus novel approaches for clinical intervention. To further study the mutational spectrum, mutation hotspots of genes and their clinical associations in patients with CRC in a southeastern Chinese population, NGS panel sequencing of specimens from 117 patients diagnosed with CRC was performed, and the significance, genetics and associations with the clinicopathological data were assessed.

 Materials and methods <sec> <title>Patients and specimen

All patients were hospitalized at Taizhou People's Hospital (Taizhou, China) between January 2011 and December 2013. Among the 117 patients enrolled, 78 patients were male, and 39 patients were female. The median age was 65 years old (range, 58-71). Diagnosis of CRC was performed independently by two pathologists based on histological examination. Sections of tumor tissues were sent to Beijing Genomics Institute (BGI) for NGS. The present study was approved by the Ethical Committee on Medical Research of the Taizhou People's Hospital. Written informed consent was obtained from all study subjects Tissue sections from 117 patients with CRC were analyzed using NGS. The clinicopathological data are summarized in Table SI. Tumor-Node-Metastasis staging was performed as reported previously (16). As in non-small cell lung cancer, patients with a low abundance of EGFR mutations may still benefit from EGFR inhibitors (17,18), thus two cutoff values for tissue gene mutation abundances were used, 5 and 0.5%. The objective was not to miss any mutations with a low prevalence, but still sufficient for beneficial results from targeted therapy.

 NGS and data analysis

Tissue sections were used for genomic DNA extraction using a kit from Amoy Diagnostics, Co., Ltd. according to the manufacturer's protocol. Only tumor cell-rich regions identified by pathologists were used for DNA extraction. NGS library construction and NGS were performed by BGI. The targeted gene regions were amplified by multiplex PCR using genomic DNA from tissue sections as the template and reagents from the Ion AmpliSeq™ Cancer Hotspot Panel v2 kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. The amplified target regions were used for NGS library construction using the Fast cfDNA Library Prep Set for MGI kit (CoWin Biosciences) according to the manufacturer's protocol. NGS was performed on a MGISEQ-2000RS platform using the proprietary sequencing kit (BGI). Speedseq (version 0.1.2: Quinlan Lab) was used for data mapping, and hg19 was used as the human reference genome. Strelka (version 2.9.2; Illumina, Inc.) was used for variant calling. For all sequencing data, Q30 sequences were >85%. The average read depth was 10,000x. The minimal read depth for variant calling was 2,000x.

 Statistical analysis

Differences between rates were compared using a χ2 test. Odds ratio (OR) analysis was performed using MedCalc (medcalc.org/calc/odds_ratio.php). P<0.05 was considered to indicate a statistically significant difference. Population data from Chinese Millionome Database (db.cngb.org/cmdb/) were used for comparison.

 Results <sec> <title>Mutation rates of common genes

Tissue gene mutation positive rates are summarized in Table I. KRAS, KIT, PIK3CA, MET and EGFR were among the most frequently mutated driver genes, and TP53, APC, CDKN2A, STK11 and FBXW7 were the most frequently mutated tumor suppressor genes (Table I). For the majority of patients with KRAS, TP53 or APC mutations, the tissue mutation frequencies were >5%, and for the majority of patients with EGFR, BRAF and CDKN2A mutations, the tissue mutation frequencies were <5% (Table I).

 Mutation spectrum and hotspots

The mutation spectrum was analyzed, and the results are summarized in Tables II and III. IDH1 R132C/H, KIT M541L, KRAS G12A/C/D/S/V, MET N375S and SMAD4 R361C/H were some of the more prominent mutation hotspots (Tables II and III). BRAF V600 mutations accounted for 40% of all BRAF mutations (Table III).

 Common synonymous variants

HRAS H27H (rs12628) and PDGFRA V824V (rs2228230) are synonymous variants, but were present in patients with CRC at high frequencies. The variant rate of HRAS H27H in CRC patients was 90/117 (76.9%; OR 5.206, P<0.001. The OR for PDGFRA V824V was 1.310, but this was not statistically significant (Table IV).

 Associations between gene mutations and clinicopathological data

Clinicopathological data and their associations with gene mutations were assessed. The majority of patients in the present study were ≥60 years, and TP53 mutations were more frequent in patients >60 years old (P<0.05, Table V). The majority of patients in the study were male, and IDH1 mutations were more frequent in male patients (P<0.05, Table V). Patients with earlier stages of cancer (TNM stages I and stage II) more frequently had a cancer of the rectum as opposed to the colon (P<0.05, Table V). Advanced TNM stage (stage IV) was associated with an increased rate of lymph node metastasis (P<0.05, Table V). There were no other significant associations observed. Gene mutation data are summarized in Table SII.

 Discussion

Accurate identification of gene mutations in CRC is critical for selecting the optimum therapeutic agents, and for predicting efficacy and prognosis. The accumulation of gene mutation data also provides important information regarding the pathogenesis of the disease and sheds light on potential novel approaches for clinical management (19-22). NGS covers considerably more genes and for much larger sequencing regions, allowing for greater sequencing sensitivity compared with Sanger sequencin or PCR tests. NGS panel studies also have the advantage of sequencing hot spot regions of a few dozen to a few hundred genes with established implications in clinical diagnosis or targeted therapy, whilst maintaining high sequencing depth compared with whole exome sequencing or whole genome sequencing. Higher sequencing depths translates to higher detection sensitivity and reliability. In CRC studies, panels of 22-genes and 50-genes are commonly used (11,23).

KRAS and NRAS mutation tests are mandatory for anti-EGFR therapy (Cetuximab, Panitumumab) (24). KRAS, BRAF and PIK3CA mutation tests are useful for predicting the efficacy of anti-EGFR agents and anti-angiogenic agents (Aflibercept, Bevacizumab, Ramucirumab, Regorafenib) (7,8,25). BRAF inhibitor Dabrafenib and MEK inhibitor Trametinib were used to treat patients with CRC who harbored a BRAF V600E mutation, and achieved positive results (26). In the present study, 12% of patients harbored BRAF mutations, and 40% of BRAF mutations were V600 mutations. PIK3CA gene encodes a PI3K catalytic subunit. The efficacy of PI3K inhibitors and mTOR inhibitors, approved for treatment of certain types of cancer or are in clinical trials, has yet to be assessed in patients with CRC (27). Regorafenib is an inhibitor of multiple tyrosine kinases, including BRAF, KIT, VEGFR and PDGFR, and used for the treatment of patients with metastatic CRC (28-30). MET N375S was found as a hotspot of mutations in the present study. The mutation may confer resistance to MET inhibition (31). The treatment of patients with CRC with MET inhibitors has yet to show promising results (32). Furthermore, MET mutations and amplifications may result in resistance to anti-EGFR and anti-BRAF therapy (33). IDH1 R132C/H were also mutation hotspots in the present study. The IDH1 inhibitor Ivosidenib achieved promising results in the treatment of patients with acute leukemia carrying IDH1 mutations (34). However, there are no reports regarding the use of this agent in CRC in clinical trials, to the best of our knowledge. HER2 mutations, such as L755S and V842I, may activate the HER2 kinase domain. Mutant HER2 may sensitize CRC towards Trastuzumab and irreversible HER inhibition (Aftinib, Neratinib, or Dacomitinib) (35). All the 6 cases with HER2 mutations in the present study carried a V842I mutation.

TP53 gene mutations are frequently identified in solid tumors including CRC (36), and in the present study 65.8% of patients with CRC harbored TP53 mutations. APR-246 was designed to restore the function of mutant p53(37). There are multiple ongoing clinical trials involving APR-246 in melanoma, ovarian cancer and hematological malignancies, but not in CRC as of yet, although the agent was shown to exhibit anti-tumor effects on CRC cells in vitro (38). Mutant APC or CTNNB1 activates the WNT/β-catenin signaling pathway and multiple agents targeting this pathway are in clinical trials for treatment of various types of cancer, including CRC (39). Although germline mutations in CDKN2A increase an individual's susceptibility to CRC (40,41), in the present study, the mutation abundance was <5% in most cases, indicative of the somatic nature. The gene product of CDKN2A or p16 protein acts as an inhibitor of CDK4, and CDKN2A mutations are common in tumors (42). Clinical trials with CDK4 inhibitor Abemaciclib or Palbociclib in solid tumors including CRC achieved some positive results (43,44). Mutations in FBXW7 were also commonly identified in the present study. The FBXW7 mutations are a negative prognostic factor for metastatic CRC (45).

The 50-gene panel used in the present study also covers certain causative genes for common hereditary CRC syndromes, such as APC for familial adenomatous polyposis, MLH1 for Lynch syndrome, PTEN for Cowden syndrome, SMAD4 for Juvenile polyposis syndrome, and STK11 for Peutz-Jeghers syndrome (46-48). A common characteristic of these syndromes is early-onset CRC (46,47). The tissue mutation frequencies of PTEN, SMAD4 and STK11 genes in most cases were <5% in the present study, indicative of the somatic nature of these mutations. When a certain hereditary CRC syndrome is suspected based on clinical manifestations or NGS screening data, verification by Sanger sequencing using DNA from the peripheral blood is recommended. MLH1 is the most common gene of mismatch repair genes that are involved in microsatellite instability, that is present in up to 15% of patients with CRC. MLH1 mutation and microsatellite instability provide important guides for CRC chemotherapy and immunotherapy in clinical settings (49,50).

NGS 50-gene panel sequencing provides comprehensive tissue gene mutation profiles. For most patients with CRC, one or several gene mutations are identified. In the present study, novel mutation spectrums and hotspots of genes commonly involved in CRC were identified, as well as some tentative and potentially relevant associations between genotypes and phenotypes. Further studies are required to investigate the associations between gene variants in tumor tissues and gene variants identified through liquid biopsy, with an expanded gene panel, with an emphasis on biomarkers for immunotherapy. Mutations of driver genes or tumor suppressor genes may provide critical information for target gene therapy as well as prognosis. A thorough understanding of the significance of the gene mutations is important in the clinical management of patients with CRC.

 Supplementary Material Table SI. Clinicopathological characteristics. Table SII. Mutation data. Acknowledgements

Not applicable.

 Funding

The work was funded in part by the 333 Plan Foundation of Jiangsu (grant no. BRA2017173), the Taizhou People's Hospital Medical Innovation Team Foundation (grant nos. CXTDA201904 and CXTDA201901), and the 2018 Taizhou People's Hospital Mandatory Project (grant no. ZL201733).

 Availability of data and materials

The datasets used and/or analyzed in the present study are available from the corresponding author on reasonable request.

 Authors' contributions

JY, ML, HY, KZ conceived and designed the project. CZ, XZ, SL, HL performed collection and quality control of clinical information, specimens and tissue sections. JY assisted with specimen processing and data collection. KZ analyzed the data and prepared the manuscript. All authors read and approved the final manuscript.

 Ethics approval and consent to participate

The present study was approved by the Ethics Committee of Taizhou People's Hospital (Taizhou, China). All subjects provided informed consent to participate in the study.

 Patient consent for publication

Not applicable.

 Competing interests

The authors declare that they have no competing interests.

 References BrayFFerlayJSoerjomataramISiegelRLTorreLAJemalAGlobal cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesCA Cancer J Clin6839442420183020759310.3322/caac.21492 ArnoldMSierraMSLaversanneMSoerjomataramIJemalABrayFGlobal patterns and trends in colorectal cancer incidence and mortalityGut6668369120172681861910.1136/gutjnl-2015-310912 ZhuJTanZHollis-HansenKZhangYYuCLiYEpidemiological trends in colorectal cancer in China: An ecological studyDig Dis Sci6223524320172779676910.1007/s10620-016-4362-4 Rodriguez-SalasNDominguezGBarderasRMendiolaMGarcía-AlbénizXMaurelJBatlleJFClinical relevance of colorectal cancer molecular subtypesCrit Rev Oncol Hematol10991920172801090110.1016/j.critrevonc.2016.11.007 StoffelEMYurgelunMBGenetic predisposition to colorectal cancer: Implications for treatment and preventionSemin Oncol4353654220162789918410.1053/j.seminoncol.2016.08.002 CarethersJMJungBHGenetics and genetic biomarkers in sporadic colorectal cancerGastroenterology14911771190 e117320152621684010.1053/j.gastro.2015.06.047 BignucoloADe MattiaECecchinERoncatoRToffoliGPharmacogenomics of targeted agents for personalization of colorectal cancer treatmentInt J Mol Sci18pii: E152220172870810310.3390/ijms18071522 DeStefanisRAKratzJDEmmerichPBDemingDATargeted therapy in metastatic colorectal cancer: Current standards and novel agents in reviewCurr Colorectal Cancer Rep15616920193113083010.1007/s11888-019-00430-6 WakaiTPrasoonPHiroseYShimadaYIchikawaHNagahashiMNext-generation sequencing-based clinical sequencing: Toward precision medicine in solid tumorsInt J Clin Oncol2411512220193051567510.1007/s10147-018-1375-3 ZhangLChenLSahSLathamGJPatelRSongQKoeppenHTamRSchleifmanEMashhediHProfiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencingOncologist1933634320142466448710.1634/theoncologist.2013-0180 Del VecchioFMastroiacoVDi MarcoACompagnoniCCapeceDZazzeroniFCapalboCAlesseETessitoreANext-generation sequencing: Recent applications to the analysis of colorectal cancerJ Transl Med1524620172922144810.1186/s12967-017-1353-y WangYLiuHHouYZhouXLiangLZhangZShiHXuSHuPZhengZPerformance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patientsVirchows Arch47295996820182970596810.1007/s00428-018-2359-4 YoussefOSarhadiVEhsanHBöhlingTCarpelan-HolmströmMKoskensaloSPuolakkainenPKokkolaAKnuutilaSGene mutations in stool from gastric and colorectal neoplasia patients by next-generation sequencingWorld J Gastroenterol238291829920172930798910.3748/wjg.v23.i47.8291 KidessEHeirichKWigginMVysotskaiaVVisserBCMarzialiAWiedenmannBNortonJALeeMJeffreySSPoultsidesGAMutation profiling of tumor DNA from plasma and tumor tissue of colorectal cancer patients with a novel, high-sensitivity multiplexed mutation detection platformOncotarget62549256120152557582410.18632/oncotarget.3041 NormannoNCervantesACiardielloFDe LucaAPintoCThe liquid biopsy in the management of colorectal cancer patients: Current applications and future scenariosCancer Treat Rev701820183005372410.1016/j.ctrv.2018.07.007 CserniGNodal staging of colorectal carcinomas and sentinel nodesJ Clin Pathol5632733520031271945010.1136/jcp.56.5.327 YangXZhuoMYeXBaiHWangZSunYZhaoJAnTDuanJWuMWangJQuantification of mutant alleles in circulating tumor DNA can predict survival in lung cancerOncotarget7208102082420162698907810.18632/oncotarget.8021 ZhouQZhangXCChenZHYinXLYangJJXuCRYanHHChenHJSuJZhongWZRelative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancerJ Clin Oncol293316332120112178856210.1200/JCO.2010.33.3757 JeongJHKimJHongYSKimDKimJEKimSYKimKPYoonYKKimDChunSMHER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAFClin Colorectal Cancer16e147e15220172822310310.1016/j.clcc.2017.01.005 LeeMSHelmsTLFengNGayJChangQETianFWuJYToniattiCHeffernanTPPowisGEfficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer modelsOncotarget7395953960820162716719110.18632/oncotarget.9153 StintzingSMiller-PhillipsLModestDPFischer von WeikersthalLDeckerTKianiAVehling-KaiserUAl-BatranSEHeintgesTKahlCImpact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: Analysis of the FIRE-3 (AIO KRK-0306) studyEur J Cancer79506020172846375610.1016/j.ejca.2017.03.023 WangXWeiQGaoJLiJLiJGongJLiYShenLClinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: A retrospective observational studyChin J Cancer368120172903721810.1186/s40880-017-0247-y FontangesQDe MendoncaRSalmonILe MercierMD'HaeneNClinical application of targeted next generation sequencing for colorectal cancersInt J Mol Sci17pii: E211720162799927010.3390/ijms17122117 BensonAB IIIVenookAPCederquistLChanEChenYJCooperHSDemingDEngstromPFEnzingerPCFicheraAColon cancer, version 1.2017, NCCN clinical practice guidelines in oncologyJ Natl Compr Canc Netw1537039820172827503710.6004/jnccn.2017.0036 SepulvedaARHamiltonSRAllegraCJGrodyWCushman-VokounAMFunkhouserWKKopetzSELieuCLindorNMMinskyBDMolecular biomarkers for the evaluation of colorectal cancer: Guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical OncologyJ Mol Diagn1918722520172818575710.1016/j.jmoldx.2016.11.001 CorcoranRBAtreyaCEFalchookGSKwakELRyanDPBendellJCHamidOMessersmithWADaudAKurzrockRCombined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancerJ Clin Oncol334023403120152639210210.1200/JCO.2015.63.2471 FernandesMSSanchesJMSerucaRTargeting the PI3K signalling as a therapeutic strategy in colorectal cancerAdv Exp Med Biol1110355320183062336510.1007/978-3-030-02771-1_4 DhillonSRegorafenib: A review in metastatic colorectal cancerDrugs781133114420182994337510.1007/s40265-018-0938-y XueWSMenSYLiuWLiuRHA meta-analysis of safety and efficacy of regorafenib for refractory metastatic colorectal cancerMedicine (Baltimore)97e1263520183029064010.1097/MD.0000000000012635 AprileGMacerelliMGiulianiFRegorafenib for gastrointestinal malignancies: From preclinical data to clinical results of a novel multi-target inhibitorBioDrugs2721322420132343587210.1007/s40259-013-0014-9 KrishnaswamySKantetiRDuke-CohanJSLoganathanSLiuWMaPCSattlerMSingletonPARamnathNInnocentiFEthnic differences and functional analysis of MET mutations in lung cancerClin Cancer Res155714572320091972364310.1158/1078-0432.CCR-09-0070 BradleyCASalto-TellezMLaurent-PuigPBardelliARolfoCTaberneroJKhawajaHALawlerMJohnstonPGVan SchaeybroeckSMErCuRICconsortiumTargeting c-MET in gastrointestinal tumours: Rationale, opportunities and challengesNat Rev Clin Oncol1456257620172837478410.1038/nrclinonc.2017.40 PietrantonioFOddoDGloghiniAValtortaEBerenatoRBaraultLCaporaleMBusicoAMoranoFGualeniAVMET-driven resistance to dual EGFR and BRAF blockade may be overcome by switching from EGFR to MET inhibition in BRAF-mutated colorectal cancerCancer Discov696397120162732528210.1158/2159-8290.CD-16-0297 DiNardoCDSteinEMde BottonSRobozGJAltmanJKMimsASSwordsRCollinsRHMannisGNPollyeaDADurable remissions with ivosidenib in IDH1-mutated relapsed or refractory AMLN Engl J Med3782386239820182986093810.1056/NEJMoa1716984 KlothMRuesselerVEngelCKoenigKPeiferMMariottiEKuenstlingerHFlorinARommerscheidt-FussUKoitzschUActivating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancerGut651296130520162600138910.1136/gutjnl-2014-309026 SoussiTWimanKGShaping genetic alterations in human cancer: The p53 mutation paradigmCancer Cell1230331220071793655610.1016/j.ccr.2007.10.001 BlandinoGDi AgostinoSNew therapeutic strategies to treat human cancers expressing mutant p53 proteinsJ Exp Clin Cancer Res373020182944895410.1186/s13046-018-0705-7 LiXLZhouJChanZLChooiJYChenZRChngWJPRIMA-1met (APR-246) inhibits growth of colorectal cancer cells with different p53 status through distinct mechanismsOncotarget6366893669920152645213310.18632/oncotarget.5385 KatohMKatohMMolecular genetics and targeted therapy of WNT-related human diseases (Review)Int J Mol Med4058760620172873114810.3892/ijmm.2017.3071 PearlmanRFrankelWLSwansonBZhaoWYilmazAMillerKBacherJBigleyCNelsenLGoodfellowPJPrevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancerJAMA Oncol346447120172797856010.1001/jamaoncol.2016.5194 YurgelunMBKulkeMHFuchsCSAllenBAUnoHHornickJLUkaegbuCIBraisLKMcNamaraPGMayerRJCancer susceptibility gene mutations in individuals with colorectal cancerJ Clin Oncol351086109520172813514510.1200/JCO.2016.71.0012 KatoSSchwaederleMDanielsGAPiccioniDKesariSBazhenovaLShimabukuroKParkerBAFantaPKurzrockRCyclin-dependent kinase pathway aberrations in diverse malignancies: Clinical and molecular characteristicsCell Cycle141252125920152569592710.1080/15384101.2015.1014149 FinnRSCrownJPLangIBoerKBondarenkoIMKulykSOEttlJPatelRPinterTSchmidtMThe cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): A randomised phase 2 studyLancet Oncol16253520152552479810.1016/S1470-2045(14)71159-3 PatnaikARosenLSTolaneySMTolcherAWGoldmanJWGandhiLPapadopoulosKPBeeramMRascoDWHiltonJFEfficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumorsCancer Discov674075320162721738310.1158/2159-8290.CD-16-0095 KorphaisarnKMorrisVKOvermanMJFogelmanDRKeeBKRaghavKPSManuelSShureiqiIWolffRAEngCFBXW7 missense mutation: A novel negative prognostic factor in metastatic colorectal adenocarcinomaOncotarget8392683927920172842441210.18632/oncotarget.16848 LoransMDowEMacraeFAWinshipIMBuchananDDUpdate on hereditary colorectal cancer: Improving the clinical utility of multigene panel testingClin Colorectal Cancer17e293-e30520182945455910.1016/j.clcc.2018.01.001 MaHBrosensLAAOfferhausGJAGiardielloFMde LengWWJMontgomeryEAPathology and genetics of hereditary colorectal cancerPathology50495920182916963310.1016/j.pathol.2017.09.004 Lindor NM, McMaster ML, Lindor CJ and Greene MH; National Cancer Institute, Division of Cancer Prevention, Community Oncology and Prevention Trials Research Group: Concise handbook of familial cancer susceptibility syndromes-second edition. J Natl Cancer Inst Monogr: 1-93, 2008. DudleyJCLinMTLeDTEshlemanJRMicrosatellite instability as a biomarker for PD-1 blockadeClin Cancer Res2281382020162688061010.1158/1078-0432.CCR-15-1678 RyanESheahanKCreavinBMohanHMWinterDCThe current value of determining the mismatch repair status of colorectal cancer: A rationale for routine testingCrit Rev Oncol Hematol116385720172869379910.1016/j.critrevonc.2017.05.006

Mutation occurrence of genes in CRC.

A, Driver genes
  0.5% as cutoff 5% as cutoff
Gene Positive cases Positive rate, % Positive cases Positive rate, %
KRAS 61 52.1 50 42.7
KIT 23 19.7 11 9.4
PIK3CA 35 29.9 19 16.2
MET 18 15.4 10 8.5
EGFR 17 14.5 1 0.9
BRAF 14 12 6 5.1
IDH1 14 12 1 0.9
PDGFR3 10 8.5 0 0
CTNNB1 8 6.8 5 4.2
IDH2 8 6.8 0 0
HER2 6 5.1 1 0.9
SMO 6 5.1 1 0.9
B, Tumor suppressor genes
  0.5% as cutoff 5% as cutoff
Gene Positive cases Positive rate, % Positive cases Positive rate, %
TP53 77 65.8 56 47.9
APC 46 39.3 34 29.1
CDKN2A 38 32.5 1 0.9
STK11 23 19.7 11 9.4
FBXW7 23 19.7 8 6.8
PTEN 19 16.2 2 1.7
SMAD4 14 12 3 2.6
MLH1 12 10.3 7 6
VHL 10 8.5 2 1.7
ATM 9 7.7 2 1.7
RB1 7 6 0 0
HNF1A 7 6 0 0
SMARCB1 6 5.1 2 1.7

Spectrum of mutations in tumor suppressor genes.

Gene Exon Mutations Positive cases, n Relative frequencyaa (%)
APC Exon16 E1554fs 12 19.7
    K1462fs 5 8.2
    Q886X 5 8.2
    R876X 5 8.2
    Others 34 55.7
CDKN2A Exon2 D125N 12 22.6
    R124H 8 15.1
    D108N 6 11.3
    V106M 6 11.3
    R128W 5 9.4
    Others 16 30.2
FBXW7 Exon8 R385C/H 10 34.5
  Exon9 R266C 6 20.7
  Exon4 R278X 6 20.7
  Exon9 Others 7 24.1
PTEN Exon6 R173C/H 5 26.3
    Others 14 73.7
SMAD4 Exon9 R361C/Hb 13 86.7
  Exon3 A118V 2 13.3
STK11 Exon8 F354L 10 37
  Exon4 D194N 6 22.2
  Exon4 E199K 6 22.2
  Exon6 Others 5 18.5
TP53 Exon4 R273C/G/H/L 19 8.5
  Exon1 R175C/H 14 6.3
  Exon2 R213Q/X 14 6.3
  Exon3 R248Q/W 12 5.4
  Exon2 R196Q/X 11 4.9
  Exon4 R280S 11 4.9
    Others 143 63.8

aRelative to total number of mutations in the same gene;

bHotspot mutation.

Spectrum of mutations in driver genes.

Gene Exon Mutations Positive cases, n Relative frequencyaa (%)
BRAF exon15 p.V600E/M 6 40
    Others 9 60
EGFR Exon19 p.A743T 5 22.7
  Exon18 p.G721S 4 18.2
  Exon19 p.746del 3 13.6
    Others 10 45.5
IDH1 Exon4 p.R132C/Hb 13 86.7
    Others 2 13.3
KIT Exon10 p.M541Lb 19 79.2
    Others 5 20.8
KRAS Exon2 p.G12A/C/D/S/Vb 41 61.2
  Exon2 p.G13D 13 19.4
  Exon4 p.A146T 5 7.5
  Exon2/3 Others 8 11.9
MET Exon2 p.N375Sb 17 94.4
  Exon14 p.R988C 1 5.6
PIK3CA Exon10 p.E545G/K 12 27.9
  Exon21 p.H1047L/R 8 18.6
  Exon21 p.R1023Q 8 18.6
  Exon2 p.R88Q 6 14
    Others 9 20.9

aRelative to total number of mutations in the same gene;

bHotspot mutation.

Frequent synonymous variants identified in the patients with colorectal cancer.

Gene Variant SNP Variant rate ORb 95% CI P-value
HRAS p.H27H rs12628 90/117 5.206 3.369-8.044 1x10-15a
PDGFRA p.V824V rs2228230 36/117 1.31 0.882-1.947 >0.05

P<0.05,

aP<0.001.

bBased on the highest possible estimated variant rate in the population from the Chinese Millionome Database CMDB.

Associations between clinicopathological data and gene mutation data.

Group Cases (%) Association with Associations
Age   TP53 mutation  
     14-59 36 (31.03%)   13
     ≥60 80 (68.97%)   64a
Sex   IDH1 mutation  
     Male 78 (66.67%)   13a
     Female 39 (33.33%)   1
Location   TNM I/II stage  
     Rectum 63 (53.85)   13a
     Colon 54 (46.15%)   1
TNM stage
     I/II/III 42 (36.21%) LN metastasis 11
     IV 74 (63.79%)   42a

aP<0.05. TNM, Tumor-Node-Metastasis staging system.